Ching-Hsien Chen, Ph.D.
Molecular Cancer Biology
- Assistant Adjunct Professor
Dr. Chen has had a passion for understanding and improving the treatment of neoplastic diseases. She has established close collaborations with physician scientists to discover novel useful biomarkers that stratify clinicopathological subtypes of solid tumors. These biomarkers will be used to predict treatment outcomes of cancer patients undergoing clinical trials with combined inhibitors specifically targeting aberrant oncogenic signaling.
Dr. Chen’s research strives to elucidate the molecular mechanisms underlying human diseases and thereby identify useful biomarkers and druggable targets in a broad range of malignancies. In the last five years, her studies have revealed multiple oncogenic complexes and have also developed the peptide-based therapeutics to mitigate cancer metastasis and drug resistance.
Currently, the research foci of Dr. Chen’s laboratory are 1) to discover potential therapeutic targets in renal cell carcinoma and polycystic kidney disease using integrated -omics data, genetic manipulations and pharmacological approaches; 2) to develop clinically viable methods of ex-vivo expansion and activation of tumor propagating cells. In addition, Dr. Chen is actively engaging in the feasibility of PIP2 retention strategies on controlling cancer progression and increasing the efficacy of chemo- or immunotherapy.
M.S., China Medical University, Taichung, Taiwan 2004
Ph.D., National Chung Hsing University, Taichung, Taiwan 2011
B.S., China Medical University, Taichung, Taiwan 2000
Internal Medicine/Cancer, National Taiwan University, Taipei, Taiwan 2011-2012
Internal Medicine/Cancer, UC Davis Medical Center, Sacramento CA 2012-2016
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Nephrology
American Thoracic Society
Honors and Awards
2016 ASN Kidney Week Travel Award, The American Society of Nephrology, USA, 2016
2015 Award for Excellence in Postdoctoral Research (Nominee), UC Davis, CA, 2015
TRDRP Postdoctoral Fellowship Award, 2014
2014 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2014
Phil Thai Memorial Award, 5th Annual Lung Research Symposium, UC Davis, CA, 2014
2013 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2013
Select Recent Publications
Chen CH, Chang WH, Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, Chen HY, Wu R, Yang PC, Chen JJW, Yu SL. HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene. 2016.
Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R and Ann DK. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget. 2015 20;6(17):15194-208.
Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, and Wu R. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am. J. Respir. Crit. Care Medicine. 2014; 190(10):1127-38.
Chen CH, Chiu CL, Adler KB and Wu R. A novel predictor of cancer malignancy: Up-regulation of MARCKS phosphorylation in lung cancer. Am. J. Respir. Crit. Care Medicine. 2014; 189(8):1002-4.
Chen CH, Thai P, Yoneda K, Adler KB, Yang PC and Wu R. A peptide that inhibits function of Myristoylated Alanine - Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene. 2014;10; 33(28):3696-706.
Chen CH, Yang MF, Liao JW, Yu SL, Chen JJW. A Novel Function of YWHAZ/β-catenin Axis in Promoting Epithelial-Mesenchymal Transition and Lung Cancer Metastasis. Mol Cancer Res. 2012; 10(10):1319-31.
Chen CH, Lin H, Chuang SM, Lin SY, Chen JJW. Acidic stress facilitates tyrosine phosphorylation of HLJ1 to associate with actin cytoskeleton in lung cancer cells. Exp Cell Res. 2010;316:2910-21.
To view a detailed list of Dr. Chen's publications, please click here.